Discussion
Sarepta Therapeutics will not reopen enrollment in a global clinical trial testing its gene therapy Elevidys (delandistrogene moxeparvovec-rokl) in boys and men with Duchenne muscular dystrophy (DMD), the company announced in a community letter. The Phase 3 trial, called ENVISION (NCT05881408), was designed to assess Elevidys’…